Difference between revisions of "Quizartinib (Vanflyta)"
Jump to navigation
Jump to search
m |
|||
Line 5: | Line 5: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
===[[Acute_myeloid_leukemia,_FLT3-positive|FLT3+ AML]]=== | ===[[Acute_myeloid_leukemia,_FLT3-positive|FLT3+ AML]]=== | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
==Also known as== | ==Also known as== |
Revision as of 18:26, 30 August 2022
Note: this drug is only approved in Japan, at this time.
Mechanism of action
FLT3 inhibitor
Diseases for which it is used
FLT3+ AML
Also known as
- Code names: AC220, ASP2689
- Brand name: Vanflyta